Vitiligo Hastalarında Topikal Kortikosterid Kulanımının Serum IL-17 Düzeyine Etkisi

Yıl 2018, Cilt: 5 Sayı: 3, 11 - 15, 04.12.2018

Sevim Karakaş Çelik Nilgün Solak Tuba Edgünlü Ümmühani Özel Türkçü

Öz

Vitiligo edinsel depigmentasyon
hastalıklarının en sık görüleni olup prevelansı %1-2’dir. Hastalık
melanositlerin kaybı ile oluşmaktadır. Yıllardır vitiligo patogenezini
açıklamaya yönelik biyokimyasal, immünolojik, genetik ve biyolojik çalışmalar
yapılmaktadır. Ancak bugüne kadar, vitiligonun etyopatogenezi ve mekanizmaları
tam olarak anlaşılamamıştır. Yakın zamana kadar vitiligo Th1 odaklı
otoimmuninflamatuar bir hastalık olarak kabul edilmekteydi. Ancak yapılan son
çalışmalar Th17’nin de vitiligo patogenezinde önemli bir rol aldığını ortaya
koymuştur. Vitiligo hastalarında IL-17 düzeyinin arttığı birçok çalışmada
gösterilmekle birlikte vitiligo hastalarında topikal kortikosteroid
kullanımının IL-17 düzeyine etkisini araştıran bir çalışma yapılmamıştır. Bu
çalışmada vitiligo hastalarında topikal kortikosteroid kullanımının IL-17 serum
düzeyine etkisinin belirlenmesi amaçlanmıştır. Çalışma kapsamında Bülent Ecevit
Üniversitesi Tıp Fakültesi Hastanesi Dermatoloji bölümünde kortikosteroid
tedavisi gören 68 vitiligo hastası ile herhangi bir tedavi almayan 16 vitiligo
hastasında serum IL-17 düzeyleri belirlenmiştir. Serum IL-17 düzeyleri topikal
kortikosteroid tedavisi alan ve almayan hastalar arasında karşılaştırıldığında
topikal kortikosteroid kullanımı ile serum IL-17 düzeyleri arasında anlamlı bir
ilişki bulunamamıştır (p>0.05). Daha önceki çalışmalarda vitiligo
hastalarında serum IL-17 düzeyinde farklılık görülmesi bu sitokinin vitiligo
patogenizinde rol oynadığını göstermekle birlikte çalışmamızda topikal
kortikosteroid kullanımının serum IL-17 düzeyine etki etmediği gösterilmiştir.

Anahtar Kelimeler

İnterlökin, IL-17, Serum Düzeyi, Sitokin, Vitiligo

The Effect of Topical Corticosteroids on Serum IL-17 Level in Vitiligo Patients

Öz

Vitiligo is
one of the most common acquired depigmenting disorders with a prevalence of
1-2% of population.  Vitiligo is caused
by the destruction of melanocytes. Over the years, the role of biochemical,
immunological, genetic, and other biological aspects in the pathogenesis of
vitiligo has been studied. So far, the exact etiopathogenesis and mechanisms of
vitiligo are not fully understood. Until recently vitiligo has been considered
mainly to be a Th1-driven autoimmune inflammatory disease defined but recent
findings have revealed a potential role for Th17 responses in the pathogenesis
of vitiligo. However, the results obtained in studies on serum levels of IL-17
are contradictory. In some studies, it has been found that increasing levels of
IL-17 in vitiligo patients but some studies decreased. The aim of our study is
to investigate serum levels of IL-17 in vitiligo patients in the Turkish
population. In the study, serum levels of IL-17 were determined in 68 vitiligo
patients who were treated with corticosteroids and 16 vitiligo patients without
any treatment in Dermatology department of Bülent Ecevit University Medical
Faculty Hospital. When serum IL-17 levels were compared between patients
receiving and not receiving topical corticosteroid treatment, no significant
correlation was found between serum IL-17 levels and topical corticosteroid use
(p>0.05). Although previous studies have shown that the difference in IL-17
serum levels that cytokine plays a role in the pathogenesis of vitiligo, but
our study indicates that topical steroid use in therapy has no effect on IL-17
levels.

Anahtar Kelimeler

Cytokine, IL-17, Interleukin, Serum Levels, Vitiligo

Kaynakça

• 1. Dunn JF. Vitiligo. Am Fam Physician. 1986;33(5):137-43.
• 2. Schwart RA. Vitiligo. Cutis 1997;60(5):239-44.
• 3. Mosher DB, Fitzpatrick TB, Ortanne JB. Disorders of Pigmentation, Hipomelanoses and Hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, eds. Fitzpatrick’s Dermatology in General Medicine, 5th ed. New York, Mc Graw Hill, 1999:936-45.
• 4. Bahadır S, Yaylı S. Childhood vitiligo: epidemiology and etiology. Türkderm. 2006; 40(3):81-6.
• 5. Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008;17(2):139-40.
• 6. Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med. 2009;360(2):160-9.
• 7. Kyriakis KP, Palamaras I, Tsele E, Michailides C, Terzoudi S. Case detection rates of vitiligo by gender and age. Int J Dermatol. 2009;48(3):328-9.
• 8. Plettenberg H, Assmann T, Ruzicka T. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. Arch Dermatol. 2003;139(5):651-4.
• 9. Puel A, Döffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291–7.
• 10. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–98.
• 11. Kovacs OS. Vitiligo. J Am Acad Dermatol. 1998;38(5):647-66.
• 12. Bhatnagar A, Kanwar AJ, Parsad D, De D. Psoralen and ultraviolet A and narrow- band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study. JEADV. 2007;21(10):1381-5.
• 13. Njoo MD, Das PK, Bos JD, Westerhof W. Association of the Köbner Phenomenon With Disease Activity and Therapeutic Responsiveness in Vitiligo Vulgaris. Arch Dermatol. 1999;135(4):407-13.
• 14. Speeckaert R, Speeckaert MM, van Geel N. Why treatments do(n't) work in vitiligo: An autoinflammatory perspective. Autoimmun Rev. 2015;14(4):332-40.
• 15. Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med. 2010;362(18):1686-97.
• 16. Jin Y, Birlea SA, Fain PR, et al Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol. 2011;131(6):1308-12.
• 17. Quan C, Ren YQ, Xiang LH, et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet. 2010;42(7):614-8.
• 18. Cheong KA, Kim NH, Noh M, Lee AY. Three new single nucleotide polymorphisms identified by a genome-wide association study in Korean patients with vitiligo. J Korean Med Sci. 2013;28(5):775-9.
• 19. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16(3):208-14.
• 20. Peters EM, Handjiski B, Kuhlmei A, et al. Neurogenic inflammation in stress-induced termination of murine hair growth is promoted by nerve growth factor. Am J Pathol. 2004;165(1):259-71.
• 21. Khan R, Satyam A, Gupta S, Sharma VK, Sharma A. Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch Dermatol Res. 2009;301(10):731-7.
• 22. Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol. 2009;60(2):256-60.
• 23. Dwivedi M, Laddha NC, Imran M, Shah BJ, Begum R. Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) in isolated vitiligo: a genotype-phenotype correlation. Pigment Cell Melanoma Res. 2011;24(4):737-40.
• 24. Kotobuki Y, Tanemura A, Yang L, et al. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res. 2012;25(2):219-30. 25. Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2011;36(3):292-7.
• 26. Ortonne J-P. Vitiligo and other disorders of hypopigmentation. In: Bolognia JL, Jorrizzo JL RR, ed. Dermatology. New York: Mosby 2008. 913–38.
• 27. Mahmoud BH, Hexsl CL, Hamzavi IH. An update on new and emerging options for the treatment of vitiligo. Skin Therapy Lett. 2008;13(2):1-6.
• 28. Zhou L, Shi YL, Li K, et al. Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. Pigment Cell Melanoma Res. 2015;28(3):324-9.
• 29. Khan R, Gupta S, Sharma A. Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-β) in patients with vitiligo. J Am Acad Dermatol. 2012;66(3):510-1.
• 30. Elela MA, Hegazy RA, Fawzy MM, Rashed LA, Rasheed H. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case- controlled study on eighty-four patients. Eur J Dermatol. 2013;23(3):350-5. 31. Tembhre MK, Sharma VK, Sharma A, Chattopadhyay P, Gupta S. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin Chim Acta. 2013;424:27-32.
• 32. Esmaeili B, Rezaee SA, Layegh P, et al. Expression of IL-17 and COX2 gene in peripheral blood leukocytes of vitiligo patients. Iran J Allergy Asthma Immunol. 2011;10(2):81-9.
• 33. Habeb AM, Al Hefnawy AM, Elsayed SB, Abo Bkr AA, Elhefnawy AM. Expression of interleukin-17 mRNA in vitiligo patients. Egypt J Dermatol Venerol. 2013;33(2):67–70.
• 34. Hegazy RA, Fawzy MM, Gawdat HI, Samir N, Rashed LA. T helper 17 and Tregs: a novel proposed mechanism for NB-UVB in vitiligo. Exp Dermatol. 2014;23(4):283-6.